David Elkins most recently served as Worldwide Vice President and CFO
for Consumer Products, Medical Devices and Corporate Functions at
Johnson & Johnson
Peter Kellogg to remain on Executive Committee as EVP, Chief
Corporate Strategy Officer until his retirement, planned for mid-2019
SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced the hiring of David V.
Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO).
Mr. Elkins will join Celgene on July 1, 2018, and become CFO effective
August 1, 2018. Mr. Elkins will succeed current CFO Peter N. Kellogg,
who will become Celgene's EVP, Chief Corporate Strategy Officer until
his retirement, planned for mid-2019.
Mr. Elkins has more than 25 years of finance, strategy, operations,
supply chain and business development experience in the United States,
Europe and emerging markets. He joins Celgene from Johnson & Johnson
(J&J), where he was Worldwide Vice President and CFO for Consumer
Products, Medical Devices and Corporate Functions with $40 billion in
revenue and a worldwide finance team of 1,800 employees. Prior to his
leadership role at J&J, Mr. Elkins was CFO for Round Rock Research, a
technology investigation and patent licensing company. From 2008 to
2012, Mr. Elkins was Executive Vice President and CFO of Becton,
Dickinson and Company, a public global medical technology company. From
1995 to 2008, he held roles of increasing responsibility at AstraZeneca,
and he began his career in finance at The Boeing Company in 1991. Mr.
Elkins holds a B.S. from the University of Delaware, an M.S. from the
University of Pennsylvania and an M.B.A. from Drexel University.
Mr. Kellogg joined Celgene as CFO in August 2014. Under Mr. Kellogg's
leadership, Celgene has delivered industry-leading performance, executed
multiple high-potential business development transactions to grow its
pipeline, and significantly strengthened its balance sheet. Mr. Kellogg
has built and led a high-performing global finance team while also
driving corporate strategy. In his new role, Mr. Kellogg will work with
the executive team to define Celgene's strategy for long-term,
sustainable growth beyond 2020. Mr. Kellogg will also work closely with
Mr. Elkins to ensure the transition of all financial and operational
matters. Both Mr. Kellogg and Mr. Elkins will report directly to Mark J.
Alles, Chairman and Chief Executive Officer, and serve on Celgene's
"The addition of David as our new Chief Financial Officer strengthens
and expands our leadership team and positions us to capitalize on our
significant opportunities through 2020 and beyond," said Mark J. Alles,
Chairman and Chief Executive Officer of Celgene Corporation. "Our
business performance will be further enhanced by Peter's continued
strategic insight and David's extensive industry experience leading
global finance teams."
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Hyperlinks are provided as a convenience and for informational purposes
only. Celgene bears no responsibility for the security or content of
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531006456/en/
Source: Celgene Corporation
News Provided by Acquire Media